The Mayo Clinic Diet for Weight-Loss Medications is designed to support you when taking semaglutide for weight loss
The FDA has approved Wegovy (semaglutide 2.4 mg), Zepbound (tirzepatide), and Saxenda (liraglutide 3 mg) for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity
October 1, 2024: Increased Reporting of Ozempic Side Effects Will Corner Novo Nordisk to Address Failure to Warn Allegations As media outlets continue to cover more stories about the side effects of Ozempic, Novo Nordisks public relations team will be cornered to maintain public trust and address these claims
A licensed clinician, not a marketing page, should make the final call on whether GLP-1 therapy and this specific program are appropriate for you
References (this section): FDA: risks/concerns with unapproved GLP-1 drugs (mentions retatrutide not FDA-approved) Drugs.com: retatrutide approval status and timeline context ClinicalTrials.gov: example Phase 3 registry listing (TRIUMPH-3) Research documentation & quality: COA/SDS, identity testing, chain-of-custody For legitimate laboratory work, documentation and quality controls matter more than marketing claims
